| Literature DB >> 23573071 |
Peter A Ajibade1, Omoruyi G Idemudia.
Abstract
Pd(II) and Pt(II) complexes of trimethoprim and pyrimethamine were synthesized and characterized by elemental analysis, UV-Vis, FTIR, and NMR spectroscopy. The complexes are formulated as four coordinate square planar species containing two molecules of the drugs and two chloride or thiocyanate ions. The coordination of the metal ions to the pyrimidine nitrogen atom of the drugs was confirmed by spectroscopic analyses. The complexes were screened for their antibacterial activities against eight bacterial isolates. They showed varied activities with the active metal complexes showing more enhanced inhibition than either trimethoprim or pyrimethamine. The Pd(II) complexes of pyrimethamine showed unique inhibitory activities against P. aeruginosa and B. pumilus, and none of the other complexes or the drugs showed any activity against these bacteria isolates. The MIC and MBC determinations revealed that these Pd(II) complexes are the most active. Structure activity relationship showed that Pt(II) complexes containing chloride ions are more active, while for Pd(II) complexes containing thiocyanate ions showed more enhanced activity than those containing chloride ions.Entities:
Year: 2013 PMID: 23573071 PMCID: PMC3610396 DOI: 10.1155/2013/549549
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Analytical data and some physical properties of the metal complexes.
| Analytical Data (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Complexes | Molecular formulae | Colour | C | H | N | Yield (%) | M.P (°C) | Cond. |
| Found (calc.) | Found (calc.) | Found (calc.) | ||||||
| [Pd(tmp)2Cl2] | C28H36N8Cl2O6Pd | Orange | 43.94 (44.37) | 5.13 (4.79) | 15.47 (14.78) | 91 | 248–250 | 11.42 |
| [Pd(tmp)2(SCN)2] | C30H36N10O6S2Pd | Yellow | 44.42 (44.86) | 3.97 (4.52) | 17.01 (17.44) | 92 | 242–245 | 9.03 |
| [Pt(tmp)2Cl2] | C28H26N8Cl2O6Pt | Pale yellow | 40.10 (39.72) | 3.79 (4.29) | 13.72 (13.24) | 92 | 135–137 | 10.13 |
| [Pt(tmp)2(SCN)2] | C30H36N10O6S2Pt | Pale yellow | 40.94 (40.40) | 4.22 (4.07) | 16.27 (15.70) | 88 | 167–171 | 7.02 |
| [Pd(pyrm)2Cl2] | C24H26N8Cl4Pd | Orange | 43.65 (42.72) | 4.26 (3.88) | 16.69 (16.61) | 90 | 259–261 | 15.62 |
| [Pd(pyrm)2(SCN)2] | C26H26N10Cl2S2Pd | Orange | 43.46 (43.37) | 3.76 (3.64) | 19.66 (19.45) | 92 | 80–82 | 40.80 |
| [Pt(pyrm)2Cl2] | C24H26N8Cl4Pt | Pale yellow | 37.99 (37.76) | 3.88 (3.43) | 14.93 (14.68) | 89 | 200–202 | 39.80 |
| [Pt(pyrm)2(NCS)2] | C26H26N10Cl2S2Pt | Pale yellow | 39.90 (38.62) | 3.77 (3.24) | 16.98 (17.32) | 97 | 180-181 | 52.80 |
Figure 1Proposed structures for the metal complexes.
Zone of inhibition exhibited by metal complexes at 40 mg/mL (mm).
| Complexes |
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| [Pd(tmp)2Cl2] | 30.0 | NI | 29.0 | NI | 32.0 | NI | 26.0 | 32.0 |
| [Pd(tmp)2(NCS)2] | 28.0 | NI | NI | 27.0 | NI | NI | NI | 28.0 |
| [Pt(tmp)2Cl2] | 32.0 | NI | 32.0 | NI | 34.0 | NI | 30.0 | 28.0 |
| [Pt(tmp)2(NCS)2] | 30.0 | NI | 25.0 | NI | 32.0 | NI | NI | 30.0 |
| [Pd(pyrm)2Cl2] | NI | 30 | 12 | NI | NI | 21 | 14 | NI |
| [Pd(pyrm)2(NCS)2] | NI | 33 | 29 | NI | NI | 20 | 33 | NI |
| [Pt(pyrm)2Cl2] | 14 | NI | 20 | 26 | NI | NI | NI | NI |
| [Pt(pyrm)2(NCS)2] | 20 | NI | 18 | NI | 28 | NI | NI | 30 |
| Pyrimethamine | 11 | NA | 13 | 12 | 10 | NA | 15 | 12 |
| Trimethoprim | 15.0 | NA | 12.0 | 18.0 | 17.0 | NA | 20.0 | 16.0 |
NI: no inhibition; NA: not applicable.
MIC values (mg/mL) of the metal complexes on selected bacteria.
| Complexes |
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| [Pd(pyrm)2Cl2] | NI | 5.0 | 0.63 | NI | NI | 0.63 | 0.31 | NI |
| [Pd(pyrm)2(NCS)2] | NI | 5.0 | 0.31 | NI | NI | 0.63 | 0.63 | NI |
| [Pt(pyrm)2Cl2] | 20.0 | NI | 10.0 | 5.0 | NI | NI | NI | NI |
| [Pt(pyrm)2(NCS)2] | 10.0 | NI | 10.0 | NI | 5.0 | NI | NI | 5.0 |
| [Pd(tmp)2Cl2] | 20.0 | NI | 10.0 | NI | 5.0 | NI | 5.0 | 10.0 |
| [Pd(tmp)2(NCS)2] | 10.0 | NI | NI | 10.0 | NI | NI | NI | NI |
| [Pt(tmp)2Cl2] | 20.0 | NI | 10.0 | NI | 10.0 | NI | 5.0 | 10.0 |
| [Pt(tmp)2(NCS)2] | 20.0 | NI | 10.0 | NI | 10.0 | NI | NI | 5.0 |
| Pyrimethamine | 20.0 | NA | 20.0 | 20.0 | 10.0 | NA | 20.0 | 10.0 |
| Trimethoprim | 20.0 | NA | 10.0 | 20.0 | 10.0 | NA | 10.0 | 10.0 |
MBC values (mg/mL) of the metal complexes on selected bacteria.
| Complexes |
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| [Pd(tmp)2Cl2] | >20.0 | NI | 20.0 | NI | 5.0 | NI | 10.0 | 20.0 |
| [Pd(tmp)2(NCS)2] | 10.0 | NI | NI | >20.0 | NI | NI | NI | NI |
| [Pt(tmp)2Cl2] | 20.0 | NI | >20.0 | NI | 10.0 | NI | 10.0 | >20.0 |
| [Pt(tmp)2(NCS)2] | >20.0 | NI | 10.0 | NI | >20.0 | NI | NI | 20.0 |
| [Pd(pyrm)2Cl2] | NI | 10.0 | 2.5 | NI | NI | 2.5 | 0.31 | NI |
| [Pd(pyrm)2(NCS)2] | NI | 10.0 | 0.63 | NI | NI | 1.25 | 2.50 | NI |
| [Pt(pyrm)2Cl2] | 20.0 | NI | 10.0 | 10.0 | NI | NI | NI | NI |
| [Pt(pyrm)2(NCS)2] | >20.0 | NI | 20.0 | NI | 10.0 | NI | NI | 20.0 |
| Pyrimethamine | >20.0 | NA | >20.0 | >20.0 | >20.0 | NA | 20.0 | >20.0 |
| Trimethoprim | >20.0 | NA | 20.0 | >20.0 | 20.0 | NA | 20.0 | 20.0 |